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Acute liver failure (ALF) is a condition with a high mortality and
morbidity for which new treatments are desperately required.
We contend that although the initial event in ALF is liver cell
death, the clinical syndrome of ALF and its complications includ-
ing multi-organ dysfunction and sepsis, are largely generated by
the immune response to liver injury.
Hepatic macrophages fulﬁl a diversity of roles in ALF, from pro-
inﬂammatory to pro-resolution. Their inherent plasticity means
the samemacrophages may have a variety of functions depending
on the local tissue environment at different stages of disease. Abet-
ter understanding of the mechanisms that regulate macrophage
plasticity during ALF will be an essential step towards realising
the potential of immune-modulating therapies that re-orientate
macrophages to promote the desirable functions of attenuating
liver injury and promoting liver repair/regenerative responses.
The key dynamics: temporal (early vs. late phase), regional (hepa-
tic vs. systemic), and activation (pro-inﬂammatory vs. pro-resolu-
tion) are discussed and the potential for novel ALF therapies that
modulate monocyte/macrophage function are described.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V.
Acute liver failure as a model of dysregulated immune-cell
driven inﬂammation
Acute liver failure (ALF) is a clinical syndrome consisting of jaun-
dice, encephalopathy, and coagulopathy due to overwhelming
hepatocyte death. Currently, speciﬁc treatments for ALF include
the use of N-acetylcysteine, liver transplantation (OLT), and best
supportive care. Although OLT has markedly improved the sur-
vival in ALF, it commits patients to life-long immunosuppression
and utilises the precious resource of a transplantable organ [1].
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which massive leucocyte inﬁltration of the injured liver is con-
trasted by a depletion and dysfunction of immune cells in the cir-
culation [2]. From a clinical perspective, it is widely accepted that
the mortality in ALF is a consequence of profound activation of
systemic inﬂammatory responses (SIRS) and its attendant com-
plications of recurrent sepsis and extra-hepatic organ dysfunc-
tion [3,4].
In this review, we show that ALF is an innate immune-driven
disorder, in which monocytes/macrophages are key determinants
of the initiation, propagation, and resolution phases of acute liver
injury. Uncontrolled immune activation leads to the clinical con-
sequences of recurrent sepsis and organ failure encountered in
this devastating condition (Fig. 1).
Key Points
• Macrophages are central to the pathogenesis of ALF, 
driving the initiation, propagation, and resolution of liver 
injury
• Macrophage plasticity provides an exciting platform 
to base therapies aimed at functional re-orientation, 
thereby promoting the resolution of inflammation
• Mechanistic biomarkers will have an important role in 
signposting the phases of immune activation in ALF, 
thus guiding the timing of intervention
• The relationship between beneficial local (hepatic) 
and deleterious systemic (circulatory) effects of key 
mediators is likely to be a challenge in developing 
immunotherapeutic strategies
Immunopathology of acute liver failureLocal immunopathology of acute liver failure: The role of tissue
macrophages
Macrophages are tissue resident members of the mononuclear
phagocytic system that play a central role in the innate immune
response to infection and sterile inﬂammation and are addition-
ally able to recruit adaptive immune cells.14 vol. 61 j 439–445
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Fig. 1. A simpliﬁed model of monocyte and macrophage function in acute liver failure. KCs detect hepatocyte death through DAMP/TLR signalling and initiate a pro-
inﬂammatory response. Bone-marrow derived monocytes trafﬁc to the liver to contribute to an expanded macrophage population which are initially pro-inﬂammatory.
During the propagation phase, immune activation is self-perpetuating with recruitment of effectors driving further cytokine and chemokine production. The release of
cytokines and vasoactive mediators into the systemic circulation provokes SIRS. Macrophage-derived mediators contribute to vascular endothelial dysfunction and
microcirculatory disturbances that result in extra-hepatic organ dysfunction. Later, the presence of pro-resolution macrophages aids tissue recovery. The spill over of anti-
inﬂammatory mediators from the liver into the circulation contributes to functional monocyte deactivation and an increased susceptibility to sepsis.
Clinical Application of Basic ScienceIn the adult liver, macrophages may originate from either a
haematopoiesis-independent, self-renewing population derived
from embryonic yolk sac cells (Kupffer cells) or from the recruit-
ment of bone marrow derived circulating monocytes [5].
Macrophage plasticity: the importance of the microenvironment
Macrophages have pleiotropic actions and diverse roles in
inﬂammation. Their protoxicant responses, such as the produc-
tion of cytokines and reactive oxygen species, are aimed at micro-
bial elimination and tissue destruction. Equally, they possess
anti-inﬂammatory properties that resolve acute inﬂammation
and trigger tissue remodelling and repair [6]. The functional char-
acteristics of macrophages have been broadly categorised as
either ‘M1’, pro-inﬂammatory, or ‘M2’, anti-inﬂammatory, phe-
notypes in a classiﬁcation analogous to TH1 and TH2 responses.
In recent years however, this deﬁnition has evolved with the rec-
ognition that the dichotomous phenotypes really represent
extremes, between which numerous macrophage activation
states exist [7]. Furthermore it is understood that macrophages
exhibit considerable plasticity during inﬂammation, being able
to reversibly transition through distinct activation states in
response to microenvironmental mediators [8].
The microenvironmental milieu is a critical determinant of
macrophage function during tissue inﬂammation. In early inﬂam-
mation the presence of TLR ligands such as HMGB1, DNA, and440 Journal of Hepatology 201pro-inﬂammatory cytokines drive macrophage polarisation
towards a classical ‘M1-like’ activation state through the activa-
tion of NF-jB and STAT1 signalling pathways. This leads to the
propagation and perpetuation of inﬂammation as it induces fur-
ther pro-inﬂammatory cytokine secretion and MHCII expression.
At the later stages of inﬂammation, macrophages undergo a func-
tional ‘‘switch’’ towards an anti-inﬂammatory or pro-resolution
‘‘M2-like’’ phenotype; with an increasing number of microenvi-
ronmental mediators responsible for this functional switch being
identiﬁed [9] (Fig. 2).
Hepatic macrophages in acute liver failure
In ALF, resident Kupffer cells are important in the initial trans-
duction and ampliﬁcation of the ‘alarm’ signal following an inju-
rious event. Hepatocyte death leads to the release of DAMPS,
which initiate the activation of innate immune and tissue
destructive responses through production of NF-jB dependent
pro-inﬂammatory mediators (e.g., TNFa, IL-1b, IL-6) and reactive
nitrogen and oxygen species [10].
Within 12 h of injury in experimental models of ALF, there is a
massive expansion in the number of hepatic macrophages. These
may be derived from proliferation of resident Kupffer cell popu-
lation and/or recruitment from the circulating pool of monocytes.
Evidence from human and experimental models of acetamino-
phen toxicity (APAP) suggests that the CCR2-dependent inﬂux4 vol. 61 j 439–445
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Fig. 2. Microenvironmental mediators are key determinants of macrophage functional polarization. This simpliﬁed schematic shows how the dominant
microenvironmental mediators can reversibly inﬂuence macrophage function. In the presence of TLR ligands and IFNc, macrophages adopt a ‘M1-like’ proﬁle with high
expression levels of pro-inﬂammatory cytokines, including IL-12 and IL-23. If the local microenvironment contains anti-inﬂammatory signals such as glucocorticoids, SPMs
(e.g., resolvins, maresins), and IL-10 an ‘M2-like’ activation state is induced. These phenotypes are simpliﬁed, with numerous potential macrophage phenotypes possible,
which are likely to be tissue-speciﬁc and depend on the precise tissue milieu at different stages of disease.
JOURNAL OF HEPATOLOGYof circulation-derived monocytes account for the observed
increase in macrophages at the early stages of liver injury [2,11].
In early experimental studies there was conﬂicting evidence
regarding the function of these newly recruited monocyte-
derived macrophages in ALF, some showing that depletion of
monocytes/macrophages to be protective, reducing liver injury
[12,13]. However, recent studies show that depletion of both
resident and inﬁltrating macrophage populations in fact impair
resolution responses of acute liver injury [11,14,15]. These incon-
sistencies probably relate to differential susceptibility of macro-
phage sub-groups to the various experimental depletion
techniques and to the inherent functional plasticity of macro-
phages during inﬂammation.
Experimental models suggest there is a biphasic macrophage
response following sterile tissue injury, namely an initial tissue
destructive, ‘M1’, response followed by a resolution/tissue repair,
‘M2’, macrophage response [16,17]. Controversy exists regarding
the origin of the M2-like macrophages. Arnold et al. showed that,
that early inﬁltrating, pro-inﬂammatory monocyte-derived
macrophages switched their functional characteristics from pro-
inﬂammatory to anti-inﬂammatory in response to micro-environ-
mental cues following experimental muscle injury [16]. In a
murinemyocardial infarctionmodel, ‘‘M2-like’’macrophageswere
derived from recruitment of committed Ly6Clo monocyte precur-
sors from the circulation at the later stages of injury [17]. Further-
more, recent data show that the tissue-resident macrophage
population proliferates in response to tissue injury and promotes
resolution responses [18]. In line with this theory, our group has
recently demonstrated a marked proliferation of resident macro-
phages within the regenerating livers of ALF patients implicating
them in the resolution of acute liver injury [2].
Systemic immunopathology of acute liver failure: Dysregulation of
systemic inﬂammatory responses
The innate inﬂammatory response has evolved to react rapidly to
tissue injury or infection in order to promote host survival. TheJournal of Hepatology 201systemic release of cytokines and chemokines is imperative for
signalling to recruit effector cells to sites of injury. In ALF, there
is massive death of hepatocytes resulting in a marked activation
of the innate immune responses with ensuing production of vast
quantities of inﬂammatory mediators. It is the ‘‘spill-over’’ of
inﬂammatory mediators from the injured liver that cause the
profound systemic disturbances and clinical manifestations of
ALF.
Pro-inﬂammatory response and SIRS
The SIRS response is a recognised clinical constellation of signs
including elevated temperature, white cell count, heart rate,
and respiratory rate that may accompany infection or sterile
inﬂammation [19]. For over a decade, it has been established that
the presence of a SIRS response, reﬂected by elevations of circu-
lating inﬂammatory mediators, is closely associated with the
development of multi-organ dysfunction and adverse outcome
in ALF [20–22].
The development of intracranial hypertension in ALF is partic-
ularly strongly associated with SIRS responses and is termed the
‘‘liver-brain proinﬂammatory axis’’ [23]. Here, pro-inﬂammatory
mediators released from the injured liver cross the blood-brain
barrier and, synergistically with elevated ammonia levels,
activate microglial cells and result in astrocyte swelling [24];
highlighting the profound effect of the inﬂamed liver on extra-
hepatic organ function.
Anti-inﬂammatory response and immune dysfunction
In parallel to the pro-inﬂammatory response, a compensatory
anti-inﬂammatory response (CARS) develops in ALF [25], which
is due to a concomitant release of anti-inﬂammatory mediators,
such as IL-10 and TGFb1, from the inﬂamed liver. Similar to other
inﬂammatory pathologies, elevated circulating concentrations of
anti-inﬂammatory mediators are detected from the very early
stages of ALF but it is the persistently high levels of IL-10 and
the CARS response that predicts a poor outcome [26]. Although
within the inﬂamed liver, the production anti-inﬂammatory4 vol. 61 j 439–445 441
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mediators serve to dampen pro-inﬂammatory responses and
limit the extent of tissue injury, their release into the systemic
circulation is the cause for the predisposition to infection and
adverse patient outcome [2].
Our group has shown that ALF patients exhibit features of
immuneparesis, typiﬁed by monocytes that are hyporesponsive
to microbial challenge [27,28]. This functional impairment in cir-
culating monocytes renders them less able to respond to second-
ary infectious insults and may account for the high rates and poor
outcomes from sepsis encountered in ALF patients. Monocyte
dysfunction and immuneparesis have been attributed to the
action of anti-inﬂammatory cytokines, in particular IL-10. How-
ever numerous other mediators released in the injured liver can
enter the systemic circulation and modulate the function of circu-
lating immune cells. One such example is secretory leucocyte
protease inhibitor (SLPI); a serine protease with immunomodula-
tory properties is produced within the injured liver during ALF
and spills-over into the systemic circulation. This molecule is
known to inhibit NF-jB signalling, neutralise neutrophil elastase,
and exert tissue-preserving effects and thus is likely to be protec-
tive within the hepatic microenvironment. However, ex vivo anal-
yses show that SLPI is capable of inducing immune deﬁcits in
monocytes that contribute to their functional impairment [27].
This example illustrates one of the major challenges in develop-
ing immune therapy for ALF in that potential molecular targets
may have differential local vs. systemic effects.Use of biomarkers in determining optimal time points for
interventional strategies in clinical practice
The paradigm of acute liver failure as a discrete injurious event
followed either by deterioration or a period of regeneration isINITIATION PROPAGATION
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Fig. 3. A schematic representation of mechanistic biomarkers in acute liver failure. B
guide the timing of potential immune therapies. The initiation stage is characterised by
Markers of macrophage activation are also elevated early in the course of ALF, but tend
regenerative phase. This model is simpliﬁed and the dynamic changes of these biomar
macrophage activation markers).
442 Journal of Hepatology 201perhaps most applicable to acetaminophen poisoning. In other
aetiologies the liver insult, by viral or autoimmune mechanisms
for example, there is on-going hepatocyte injury and attempted
resolution and regeneration will occur concomitantly. However
as acetaminophen hepatotoxicity is the commonest and best-
studied cause of ALF in the USA and UK a picture of the different
phases of injury and inﬂammation in this condition is emerging
through the measurement of serum biomarkers (Fig. 3). These
biomarkers have potential clinical utility, not only in determining
prognosis in ALF, but in deﬁning the optimal timing of appropri-
ate immune interventions.
Initiation
In the early, ‘initiation’ stages of acetaminophen-induced ALF
markers of cell death predominate, with total HMGB1 and total
and caspase-cleaved cytokeratin-18 showing signiﬁcant eleva-
tions that sharply decline between day 1 and 3 of admission
[29,30]. microRNA 122 has also been shown to be a speciﬁc mar-
ker of hepatocyte death that appears transiently in the very early
stages of liver injury [31].
Propagation
Macrophage activation markers are also seen early in the course
of liver injury, but these tend to persist at high levels in serum for
at least 3 d, reﬂecting persisting stimulation of macrophages after
the majority of hepatocyte death has ceased. This phase can be
considered the ‘propagation phase’, when immune stimulation
is self-perpetuating and un-coupled from the initial injurious
stimulus.
Serum neopterin and the soluble form of the macrophage
scavenger receptor CD163 (sCD163) have been proposed asRESOLUTION
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iomarkers may help to deﬁne the stage of hepatic injury in acute liver failure and
the presence of biomarkers of hepatocyte death, which peak early and decline.
to persist. Late markers of regeneration and immunosuppression characterise the
kers are likely to be most instructive (i.e., falling cell death markers, with rising
4 vol. 61 j 439–445
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surrogate markers of macrophage activation in ALF [32,33]. It is
important to note that although sCD163 is a biomarker of macro-
phage activation following liver injury, it does not reﬂect the
functional characteristics of these cells per se. Both markers
remain elevated in ALF between day 1 and 3 following admission
and levels correlate with severity of extra-hepatic complications
and mortality. Serum levels of sCD163 were seen to diverge
between day 1 and 3 in spontaneous survivors and those who
died or required transplantation, with persisting macrophage
activation indicative of poor prognosis [33].
Acetylated HMGB1 is secreted by monocytes and macro-
phages as a pro-inﬂammatory mediator, unlike the non-acety-
lated form that is more widely expressed and passively
released by necrotic cells. Levels of acetylated HMGB1 are
observed in ALF and correlate well with poor outcome. In both
a rodent experimental model and ALF patient group acetylated
HMGB1 elevations were a delayed event (15 h and 3 d post-injury
in mice and humans respectively) after markers of hepatocyte
death had declined [29,34]. This temporal relationship has mech-
anistic implications, suggesting that activated macrophages are
unlikely to be involved in the initial phase of hepatocyte injury.Regeneration/resolution
A number of serum markers of hepatocyte regeneration have
been investigated in acute liver failure. Alpha-fetoprotein (aFP)
is elevated on day 1 in liver injury, suggesting the regenerative
hepatic response occurs early. A rise in aFP between day 1 and
3 is associated with a better outcome from ALF, showing the
importance of early and sustained liver regeneration to survival
[35,36]. Hyperphosphataemia in the presence of renal dysfunc-
tion late in the course of ALF is associated with a poor outcome
as it is a marker of absent or limited hepatic regeneration [37].
In patients with signiﬁcant hepatic regeneration, hyperphosphat-
aemia does not develop despite renal dysfunction as hepatocyte
proliferation consumes phosphate.
Multi-organ dysfunction and systemic immune paresis are
common manifestations of ALF and can be observed late in the
course of ALF. Systemic immune dysfunction as evidenced by a
monocyte phenotype characterised by low HLA-DR, high CD163
expression is associated with sepsis risk and poor prognosis [28].Potential approaches to improve outcomes in acute liver
failure
Attenuating the severity of acute liver injury during the initiation
and propagation phases
Inhibition of innate immune activation
At the initiation phase of ALF, immune therapy should be tar-
geted at restricting the massive activation of the innate immune
system. As the early communication of cellular distress or death
from hepatocytes to KCs is through DAMP:TLR interactions and
NFjB signalling, these are clear molecular targets for immune
therapy. Inhibition of signalling through TLR2, TLR3, and TLR4
has been shown to ameliorate liver injury in murine models of
acetaminophen hepatotoxicity [38–40]. HMGB1 inhibition has
also shown some beneﬁt in an experimental model [40]. In a
rodent model of acetaminophen toxicity, knockout of the NFjBJournal of Hepatology 201p50 gene caused a decrease in inﬂammatory cytokine production,
though no overall effect on outcome.
Strategies that target this initial signalling pathway are likely
to be most effective when administered very early in disease
onset, while serum markers of cell death remain high and prior
to the propagation phase of liver injury. This provides a clinical
challenge, as the time window in which these therapies could
be effective is likely to be short. A further important consider-
ation is that a degree of immune activation is adaptive and nec-
essary for the resolution of tissue injury. The recruitment and
expansion of a population of tissue macrophages at the site of
injury is associated with effective phagocytosis and facilitation
of tissue regeneration. Strategies that limit early immune activa-
tion will need to be carefully applied so as not to prevent macro-
phage recruitment and consequently delay hepatic regeneration.
Clearly further work is required before these approaches are tri-
alled in patients, however they do offer the promise of curtailing
the initial immune activation and its deleterious downstream
consequences.
Promoting pro-resolution macrophage polarisation
Accepting that macrophages have a role in the initiation of injury
in ALF, yet are also necessary for the later resolution of inﬂamma-
tion and that due to their inherent plasticity it is likely to be the
same cells involved in both effects, it is clear that targeting mac-
rophages or inhibiting their recruitment could prove counterpro-
ductive. Rather, a therapeutic approach that aims to utilise key
mediators to promote an early switch in macrophage function
to favour a pro-resolution phenotype should be considered. In
ALF, this offers the potential to accelerate the resolution of injury
and expedite hepatocyte regeneration with the recovery of vital
homeostatic functions.
Steroids are known to promote macrophage resolution
responses, however their systemic application in ALF remains
controversial [41]. Using a more targeted approach, a small trial
of intra-arterial steroid injection for patients with fulminant
hepatic failure has shown promise, though this requires further
evaluation [42].
Ideally a therapy of this type would be able to target activated
hepatic macrophages without causing a concomitant immuno-
suppressive effect on circulating monocytes and would permit
monocyte-derived macrophage recruitment to secondary sites
of inﬂammation or infection. Recent advancements in our under-
standing of macrophage plasticity will hopefully lead to the
development of novel therapeutic agents for use in ALF and other
sterile inﬂammatory conditions.
Limiting the systemic effects of SIRS
As described above, many of the most clinically signiﬁcant seque-
lae of ALF are due to the multi-organ effects of a ‘storm’ of inﬂam-
matory mediator release from the acutely inﬂamed liver.
Removal of these mediators from the circulation offers the prom-
ise of reducing the collateral damage of overwhelming innate
immune activation. There is limited evidence that artiﬁcial liver
support devices, based on an albumin dialysis principle, are able
to remove circulating cytokines [43,44], with many studies ﬁnd-
ing no signiﬁcant net removal of cytokines following liver sup-
port treatment [45,46]. Clinical studies indicate that
plasmapheresis may be a potential therapeutic option in ALF,
reducing the magnitude of the SIRS response and concentrations
of circulating inﬂammatory mediators [47,48].4 vol. 61 j 439–445 443
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In contrast to the non-speciﬁc effect of plasmapheresis, indi-
vidual cytokines may be targeted by immune therapies. The util-
ity of this approach is likely to be undermined by the
considerable redundancy that exists in inﬂammatory cytokine
signalling.Strategies to reverse immunoparesis
In established ALF, sepsis is the most important cause of mortal-
ity. Reversing immunoparesis and restoring immune competence
to these patients offers the possibility of reducing their predispo-
sition to infection while allowing time for liver recovery. Evi-
dence suggests that peripheral monocyte dysfunction is driven
by the spill over of anti-inﬂammatory mediators such as IL-10
and SLPI from the liver. A potential therapeutic option would
therefore be plasmapheresis, which could remove these soluble
mediators from the circulation and as far as possible ‘isolate’
the liver from the systemic circulation. Inhibition of key media-
tors of immuneparesis (e.g., SLPI) may impact on the hepatic
regenerative process but should be evaluated as redundancy in
resolution pathways in the liver may allow inhibition of a medi-
ator that would improve systemic monocyte function without
impairing liver recovery.Conclusion
ALF is characterised by profound activation of innate immune
responses, with monocytes/macrophages being the main orche-
strators of disease evolution. Immunomodulatory strategies tar-
geting the function of monocyte/macrophages offer the
possibility of reducing the systemic sequelae of ALF whilst pro-
moting hepatic repair processes.
To develop clinical relevant immunomodulatory strategies in
ALF, we also need to focus the research on understanding the
underlying mechanisms of liver injury and biomarkers that accu-
rately reﬂect the distinct phases of liver injury rather than merely
relying on predictive biomarkers of disease severity.
At disease initiation, strategies should be considered that
attenuate the initiating pro-inﬂammatory response and mitigate
the deleterious systemic effects of pro-inﬂammatory cytokine
secretion, without inhibiting the necessary migration of mono-
cytes to the injured liver. We should aim to limit the propaga-
tion phase of liver injury by early re-orientation of hepatic
macrophage function towards a ‘pro-resolving’ phenotype. It is
hoped that an increased understanding of the complex factors
that govern tissue macrophage plasticity may allow manipula-
tion of macrophage function to shorten the duration of inﬂam-
mation and expedite tissue repair. During the resolution phase
of liver injury, immune modifying strategies are required that
will reverse the immuneparesis and reduce susceptibility to
infection whilst allowing hepatic regenerative responses to con-
tinue unhindered.Conﬂict of interest
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